Stockwatch: The punctuations of life science investment
This article was originally published in Scrip
Executive Summary
As investors in the life sciences sector bask in the glow of another significant monthly return, it is clear that not even the Ukrainian crisis can dampen the advance of the biotech sector. There were some tense days last week when virtually all pharmaceutical and biotechnology stocks went down with the market (and those recent biotech IPOs moved down much more than most other stocks), but by the end of the week the bankers touting IPOs and secondary offerings had re-emerged from their bunkers, swapped their tin hats for their toupees and started to barrack investors again.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.